Dow component Merck (MRK +2.85%) may be a juggernaut of the pharmaceutical industry, but there are plenty of reasons to be both bullish and bearish on this stock. In our brand new premium research report, our senior biotech analyst breaks down Merck's market opportunities, biggest threats, discusses the company's management, and offers compelling reasons to both buy and sell this stock.
Here is a small sample of what you'll find in the full report:
Three reasons to buy
- Merck is losing revenue from Singulair's patent expiration, but the company has a diversified portfolio that will help to mitigate this loss. Also, its diabetes drugs, Januvia and Janument, and HIV therapeutic Isentress displayed strong growth in recent quarters.
- The company is searching for additional blockbuster drugs -- and has the pipeline to prove it. Merck has several drugs in phase 2 and phase 3 clinical trials. Investors need to monitor the progress of these studies and hope that many make it through Food and Drug Administration approval.
- Merck's dividend yield, near the top of its peer group, can be attractive to long-term income investors.
We hope you enjoyed this sneak peek at our new premium research report on Merck. To get more in-depth information on this stock -- including an in-depth look at Merck's market opportunities -- click here today to learn more.
